Our redemption liabilities represent our liabilities arising from the obligations to repurchase the partnership interests of Fuyang Lianchuang, the shareholding platform for our equity scheme to incentivize directors, supervisors, senior management and other key employees, which was implemented in 2018.
Financial Information · 第 304 页
We had redemption liability of only approximately RMB10,000 as at 31 December 2024 as we repurchased all of the partnership interests in Fuyang Lianchuang from the participating personnel, and derecognised the redemption liabilities in August 2024.
Financial Information · 第 304 页
As at 31 December 2023, 2024 and 2025, our non-trade nature amount due to related parties were approximately RMB0.9 million, RMB16.6 million and nil, respectively, primarily due to the interest-free advance we obtained from our related parties for the repurchase of the partnership interests in Fuyang Lianchuang from the participating personnel.
Our prepayments, other receivables and other assets increased from RMB8.7 million as of December 31, 2023 to RMB120.1 million as of December 31, 2024, which was primarily due to an increase of RMB105.6 million in receivables in connection with the Reorganization, representing the receivables due from our shareholders who had not fully performed their capital injection obligations to our Company, as part of our Reorganization.
北京海致科技集团股份有限公司Beijing Haizhi Technology Group Co., Ltd.02706.HK
重组产生的关联方往来余额已结清
As of December 31, 2022, 2023, 2024, September 30, 2025 and December 31, 2025, we had amounts due to related parties of RMB39.2 million, RMB510.1 million, nil, nil and nil, respectively.
Financial Information · 第 399 页
Our amounts due to related parties decreased significantly from RMB510.1 million as of December 31, 2023 to nil as of December 31, 2024 and September 30, 2025, primarily because our amount due to related parties had been settled in accordance with our relevant contractual requirements.
Financial Information · 第 399 页
Our prepayments, deposits and other receivables increased significantly from RMB26.0 million as of December 31, 2022 to RMB558.1 million as of December 31, 2023, and then decreased by 96.7% to RMB18.3 million as of December 31, 2024, primarily because we had amounts due from certain shareholders of our Company of RMB532.7 million in 2023, mainly as a result of the Reorganization.
无锡先导智能装备股份有限公司WUXI LEAD INTELLIGENT EQUIPMENT CO., LTD.00470.HK
与拉萨新道的非贸易往来款1,160万元已结清
There were amounts due to Lhasa Xindao Venture Investment Co., Ltd. as of December 31, 2023 and 2024, which remained at RMB11.6 million and were in relation to payment of interest expenses on lease liabilities (non-trade in nature), and have been settled.
Financial Information · 第 337 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm’s-length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
Our amounts due to a related party represented amounts of borrowings to be repaid to Mr. Jianwei Liu, our executive Director, which were non-trade, unsecured and interest-free.
Financial Information · 第 308 页
All of such borrowings will be settled prior to Listing.
Financial Information · 第 310 页
Our Directors confirm that all related party transactions during the Track Record Period were conducted on an arm’s-length basis, and would not distort our results of operations over the Track Record Period or make our historical results over the Track Record Period not reflective of our expectations for our future performance.
During the Track Record Period, we had certain deposits and other receivables from an entity controlled by certain shareholders, which were non-trade in nature. As of the Latest Practicable Date, all such amounts were fully settled.
Financial Information · 第 387 页
Our Directors are of the view that the related party transactions set out in Note 36 of the Accountant's Report in Appendix I to this prospectus were conducted in the ordinary course of business and with normal commercial terms between the relevant parties.
Our prepayments, other receivables and other assets increased from RMB120.9 million as of December 31, 2022 to RMB348.7 million as of December 31, 2023, primarily due to an increase of RMB139.1 million in prepayments for contract manufacturing of TG Gen 2 and an increase of RMB105.2 million in receivables from shareholders, representing unpaid capital contributions from certain shareholder.
Financial Information · 第 313 页
We did not have non-trade related balance with related parties as of June 30, 2025.
During the Track Record Period, to better utilize the excessive cash for higher returns, we participated in the treasury management scheme managed by JD Group, through transferring excessive cash to JD Group and charges interest accordingly.
Financial Information · 第 346 页
The amounts due from JD Group primarily represented balances with JD Group, including (i) the profits generated by the Remaining Listing Business in JD Group and held by JD Group on behalf of us, which were unsecured, interest-free and repayable on demand, and (ii) our participation in the treasury management scheme managed by JD Group, which were unsecured, and interest bearing.
Financial Information · 第 347 页
We have received the amounts under the treasury management scheme paid by JD Group in cash, and terminated this arrangement in 2023.
上海宝济药业股份有限公司Shanghai Bao Pharmaceuticals Co., Ltd.02659.HK
关联方非贸易往来余额
Our amounts due from related parties represented (i) our short-term loan to one of our Share Incentive Platforms to support its normal operations, and (ii) advances to a Supervisor for coverage of reimbursable expenses, such as traveling and transportation expenses, incurred during her performance of obligations.
Financial Information · 第 438 页
All non-trade balances with related parties and capital injection from shareholders had been fully settled as of December 31, 2024 and we do not expect to enter into any such arrangements thereafter.
Financial Information · 第 438 页
Our Directors confirm that each of the significant related party transactions during the Track Record Period was conducted on an arm's length basis, and would not distort our results of operations over the Track Record Period or make our historical results not reflective of our future performance.
河北海伟电子新材料科技股份有限公司Hebei Haiwei Electronic New Material Technology Co., Ltd.09609.HK
关联方余额及关联方财务担保收入
Our amounts due to related parties decreased by 96.3% from RMB123.1 million as of December 31, 2022 to RMB4.5 million as of December 31, 2023, primarily because we settled all of the outstanding amounts of trade nature due to Haiwei Petrochemical and Haiwei Transportation, a related party controlled by the father of Mr. Song.
Financial Information · 第 281 页
The outstanding balances with related parties of non-trade nature are expected to be fully settled upon the Listing.
Financial Information · 第 287 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted in the ordinary and usual course of business and on an arm’s length basis, and they did not distort our results of operations during the Track Record Period or make our historical results during the Track Record Period not reflective of our future performance.
We had amounts due from related parties of RMB4,260.1 million, RMB3,752.4 million, nil and nil as of December 31, 2022, 2023, 2024 and May 31, 2025, respectively.
Financial Information · 第 384 页
Our amounts due from related parties decreased from RMB4,260.1 million as of December 31, 2022 to RMB3,752.4 million as of December 31, 2023, and further to nil as of December 31, 2024 and May 31, 2025, primarily due to the settlement of the amount due from Innovation Group, mainly as a result of the offset of considerations among related parties as part of the Reorganization.
Financial Information · 第 384 页
All our amounts due to related parties will be settled before Listing.
We have historically funded our working capital and other capital requirements principally from our operating activities, advances or loans from related parties and bank borrowings.
Financial Information · 第 381 页
The abovementioned amounts due from related companies and amount due from Century BVI were non-trade in nature.
Financial Information · 第 376 页
The amounts due from the related companies were repaid in 2024.
紫金黄金国际有限公司ZIJIN GOLD INTERNATIONAL COMPANY LIMITED02259.HK
与紫金矿业的现金池存款及非贸易往来余额
As of December 31, 2022, 2023 and 2024 and June 30, 2025, the balance of such deposit of idle cash amounted to US$124.3 million, US$134.3 million, US$233.4 million and US$148.4 million, respectively.
Financial Information · 第 484 页
The non-trade balances with related parties will be settled by 2028, and the non-trade balances with Zijin Mining will be no more than US$750 million prior to the Listing.
Financial Information · 第 505 页
Our Directors confirmed that each of the related party transactions set out in note 45 to the Accountants’ Report set out in Appendix I to this Prospectus was conducted in the ordinary course of business on an arm’s length basis and with normal commercial terms between the relevant parties.
All loans, advances, which are of a non-trade nature, due to and from the related parties are expected to be settled before the Listing.
Financial Information · 第 421 页
It is the view of our Directors that our transactions with related parties during the Track Record Period was conducted on an arm's length basis and with normal commercial terms between the relevant parties.
The amounts due from related parties are non-trade in nature and are expected to be settled before the Listing.
Financial Information · 第 360 页
We enter into transactions with our related parties from time to time during our ordinary course of business and on terms comparable to the terms of transactions with other entities that are not related parties, details of which are set forth in Note 32 of the Accountants' Report.
Financial Information · 第 380 页
Our Directors believe that each of the related party transactions set out in Note 32 to the Accountants' Report was conducted on an arm's-length basis and would not distort our track record results or make our historical results not reflective of our future performance.
Amounts due to related parties, which are non-trade in nature, relate to the 2021 Reorganization.
Financial Information · 第 381 页
As of December 31, 2022, 2023 and 2024, March 31, 2025 and July 31, 2025, our amounts due to related parties were RMB334.3 million, RMB340.1 million, RMB335.3 million, RMB5.3 million (US$0.7 million) and nil, respectively.
Financial Information · 第 397 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm’s length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
As of December 31, 2022, 2023 and 2024 and as of April 30, 2025, we had loans from related parties of RMB1,027.6 million, RMB1,065.1 million, nil, and nil, respectively. These loans were mainly used for supplementing our working capital and optimizing our debt structure by repaying certain loans from financial institutions and were non-trade in nature.
Financial Information · 第 258 页
Our Directors confirm that these transactions were conducted in the ordinary course of our business, on an arm's length basis and with normal commercial terms between the relevant parties.
As of December 31, 2022, 2023 and 2024, we recorded non-trade related amounts due from related parties of RMB180.6 million, RMB185.4 million and RMB86.8 million, respectively, and recorded non-trade related amounts due to related parties of RMB108.2 million, RMB17.0 million and nil, respectively.
Financial Information · 第 586 页
Regarding Huangshan Shoukang Hospital, which is one of our Managed Hospital and Health Service Center, from whom we recorded corresponding revenue of RMB67.2 million, RMB137.5 million and RMB111.6 million with respect to our supply of pharmaceuticals, medical equipment and consumables for the Track Record Period, respectively.
Business · 第 337 页
In particular, we recognized a net repayment of RMB96.8 million from Huangshan Shoukang Hospital for the year ended December 31, 2024.
Other receivables was a loan to a shareholder and was collected in December 2023.
Financial Information · 第 437 页
Our Directors confirm that the related party transactions set out in Note 28 to the Accountants’ Report in Appendix I to this prospectus were conducted in the ordinary course of business on arm’s length basis and with reference to the normal commercial terms of each party.